MK-1903

Overview

MK-1903 is an orally active full agonist of GPR109a/HCAR2 , with an EC 50 of 12.9 nM. MK-1903 activates antilipolytic and vasodilatory pathways, reduces plasma free fatty acid levels, and induces skin flushing. MK-1903 stimulates the expression of HCAR2 protein and regulates the inflammatory response of microglia. MK-1903 prevents the enhanced firing activity of spinal nociceptive neurons. MK-1903 triggers the release of MMP-9 and the formation of NET . MK-1903 can be used in the research of dyslipidemia and neuroinflammation-based central nervous system diseases.

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > CNS Infection | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > GPR109A | Products > Signaling Pathways > MMP

Product Information

• Catalog No.: HY-107581
• CAS No.: 1268882-43-4
• Molecular Formula: C8H8N2O2
• Molecular Weight: 164.16
• Purity: 99.68%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.08 mg/mL (12.67 mM); Clear solution
• Availability: In-stock

Source

Original product source